XCSECHEMM
Market cap1.19bUSD
Dec 20, Last price
491.00DKK
1D
-0.16%
1Q
14.19%
Jan 2017
1,319.08%
IPO
2,539.78%
Name
Chemometec A/S
Chart & Performance
Profile
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal production; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. It also provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. The company was incorporated in 1997 and is headquartered in Allerød, Denmark.
Valuation
Title DKK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
Income | ||||||||||
Revenues | 407,870 -8.22% | 444,401 3.74% | 428,391 52.38% | |||||||
Cost of revenue | 48,668 | 55,471 | 91,769 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 359,202 | 388,930 | 336,622 | |||||||
NOPBT Margin | 88.07% | 87.52% | 78.58% | |||||||
Operating Taxes | 40,302 | 51,693 | 43,751 | |||||||
Tax Rate | 11.22% | 13.29% | 13.00% | |||||||
NOPAT | 318,900 | 337,237 | 292,871 | |||||||
Net income | 136,284 -23.72% | 178,667 12.04% | 159,469 80.49% | |||||||
Dividends | (104,415) | (69,610) | ||||||||
Dividend yield | 1.97% | 0.53% | ||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 3,181 | 3,517 | 1,934 | |||||||
Long-term debt | 3,798 | 9,792 | 10,629 | |||||||
Deferred revenue | (18,019) | (14,930) | ||||||||
Other long-term liabilities | 3,400 | 2,100 | 1,830 | |||||||
Net debt | (289,167) | (465,928) | (338,946) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 129,002 | 154,146 | 176,860 | |||||||
CAPEX | (20,947) | (40,816) | (55,916) | |||||||
Cash from investing activities | (43,494) | (40,831) | (56,046) | |||||||
Cash from financing activities | (105,715) | (2,925) | (69,012) | |||||||
FCF | 345,232 | 183,414 | 338,488 | |||||||
Balance | ||||||||||
Cash | 296,146 | 316,571 | 209,025 | |||||||
Long term investments | 162,666 | 142,484 | ||||||||
Excess cash | 275,752 | 457,017 | 330,089 | |||||||
Stockholders' equity | 565,294 | 428,627 | 714,384 | |||||||
Invested Capital | 297,118 | 145,653 | (34,200) | |||||||
ROIC | 144.05% | 605.17% | 3,502.71% | |||||||
ROCE | 61.79% | 65.66% | 108.30% | |||||||
EV | ||||||||||
Common stock shares outstanding | 17,402 | 17,402 | 17,402 | |||||||
Price | 304.60 -34.64% | 466.00 -38.44% | 757.00 -10.25% | |||||||
Market cap | 5,300,795 -34.64% | 8,109,555 -38.44% | 13,173,677 -10.25% | |||||||
EV | 5,011,628 | 7,643,627 | 13,191,910 | |||||||
EBITDA | 376,413 | 409,399 | 356,660 | |||||||
EV/EBITDA | 13.31 | 18.67 | 36.99 | |||||||
Interest | 183 | 1,088 | 1,517 | |||||||
Interest/NOPBT | 0.05% | 0.28% | 0.45% |